Inclusion of Obese Participants in Drug Development: Reflections on the Current Landscape and a Call for Action.

The article discusses the importance of including obese participants in clinical trials during drug development, emphasizing the need for a comprehensive approach that considers disease epidemiology, comorbidities, and safety. Topics include the impact of obesity on drug pharmacology, the challenges in current dosing paradigms for obese populations, and the proposed roadmap for expanding the inclusion of obese participants in drug development to optimize dosage and benefit-risk profiles.